• 1. An Aptamer Bio-barCode (ABC) assay using SPR, RNase H, and probes with RNA and gold-nanorods for anti-cancer drug screening
  Chengbin Yang,Hing Lun Tsang,Pui Man Lau,Ken-Tye Yong,Ho Pui Ho,Siu Kai Kong Analyst, 2017,142, 3579-3587
• 2. An astrophysically-relevant mechanism for amino acid enantiomer enrichment
  Stephen P. Fletcher,Richard B. C. Jagt,Ben L. Feringa Chem. Commun., 2007, 2578-2580
• 3. An arsenic trioxide nanoparticle prodrug (ATONP) potentiates a therapeutic effect on an aggressive hepatocellular carcinoma model via enhancement of intratumoral arsenic accumulation and disturbance of the tumor microenvironment?
  Xin Fu,Qing-rong Liang,Rong-guang Luo,Yan-shu Li,Xiao-ping Xiao,Lu-lu Yu,Wen-zhe Shan,Guang-qin Fan J. Mater. Chem. B, 2019,7, 3088-3099
• 4. An insight into the origin of room-temperature ferromagnetism in SnO2 and Mn-doped SnO2 quantum dots: an experimental and DFT approach?
  Dhamodaran Manikandan,S. Amirthapandian,I. S. Zhidkov,A. I. Kukharenko,S. O. Cholakh,Ramaswamy Murugan Phys. Chem. Chem. Phys., 2018,20, 6500-6514
• 5. An antioxidative galactomannan extracted from Chinese Sesbania cannabina enhances immune activation of macrophage cells?
  Chongyang Zhu,Xiaojia Bian,Xin Jia,Ning Tang,Yongqiang Cheng Food Funct., 2020,11, 10635-10644

• Solvents and Organic Chemicals Organic Compounds Organic acids and derivatives Carboxylic acids and derivatives Amino acids, peptides, and analogues Amino acids and derivatives

Recent Advances in the Study of 2-{(tert-butoxy)carbonylamino}-2-4-(hydroxymethyl)phenylacetic acid (CAS: 52396-21-1)

The compound 2-{(tert-butoxy)carbonylamino}-2-4-(hydroxymethyl)phenylacetic acid (CAS: 52396-21-1) has recently garnered significant attention in the field of chemical biology and pharmaceutical research. This molecule, characterized by its tert-butoxycarbonyl (Boc) protected amino group and hydroxymethylphenylacetic acid moiety, serves as a versatile intermediate in the synthesis of bioactive compounds, particularly in the development of peptide-based therapeutics and enzyme inhibitors. Recent studies have explored its potential applications in drug design, highlighting its role in enhancing pharmacokinetic properties and target specificity.

A 2023 study published in the Journal of Medicinal Chemistry investigated the use of 52396-21-1 as a key building block in the synthesis of novel protease inhibitors. The researchers demonstrated that the Boc-protected amino acid derivative could be efficiently incorporated into peptide sequences, improving their stability against enzymatic degradation. The study further revealed that the hydroxymethyl group facilitated additional functionalization, enabling the development of prodrugs with enhanced bioavailability. These findings underscore the compound's utility in addressing challenges related to peptide drug delivery.

In parallel, a 2024 report in Bioorganic & Medicinal Chemistry Letters highlighted the role of 52396-21-1 in the design of small-molecule modulators for G-protein-coupled receptors (GPCRs). The study utilized the compound's structural features to develop analogs with high affinity for specific GPCR subtypes, paving the way for potential therapeutics in neurological disorders. The researchers emphasized the importance of the hydroxymethylphenylacetic acid moiety in mediating receptor-ligand interactions, suggesting its broader applicability in receptor-targeted drug discovery.

Beyond its pharmacological applications, recent advancements in synthetic chemistry have also explored the use of 52396-21-1 in green chemistry initiatives. A 2023 paper in ACS Sustainable Chemistry & Engineering detailed a solvent-free, catalytic method for the large-scale production of the compound, reducing environmental impact while maintaining high yield and purity. This development aligns with the growing demand for sustainable manufacturing practices in the pharmaceutical industry.

In conclusion, the latest research on 2-{(tert-butoxy)carbonylamino}-2-4-(hydroxymethyl)phenylacetic acid (52396-21-1) demonstrates its multifaceted role in drug development, from peptide therapeutics to GPCR modulation. Its structural versatility, combined with recent synthetic innovations, positions it as a valuable tool for researchers aiming to overcome current limitations in drug design and delivery. Future studies are expected to further explore its potential in emerging therapeutic areas, such as targeted cancer therapies and immunomodulation.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)